Health ❯ Healthcare ❯ Drug Development

Clinical Research

Patient Enrollment Efficacy Studies Phase 3 Trials Peptide Inhibitors SpringWorks Therapeutics Therapeutics Genetic Studies Alzheimer's Focus PIPI Drugs Regulatory Approval Fabhalta Eli Lilly Semaglutide Phase 3 Studies Eli Lilly Trials Patient Safety

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

The INHBE-targeting siRNA produced durable Activin E suppression supporting infrequent dosing.

FDA Grants Breakthrough Therapy Designation to Incyte’s CALR‑Targeting Antibody as ASH Data Show Early Efficacy in Myelofibrosis

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Novartis’ Fabhalta Slows Kidney Function Decline in Final Phase 3 IgAN Results

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials